Japan Remains Primary Outlet For Innovative Brands As Attention Shifts To China – IMS
This article was originally published in PharmAsia News
IMS sees more opportunity for new brands in Japan even as China is expected to become the second-largest pharma market.
You may also be interested in...
Whether Daiichi Sankyo will be able to claim damages from Ranbaxy’s former owners will depend on what Daiichi Sankyo knew before the acquisition, and its chances of proving misrepresentation may be slim.
Prosecutors are looking into allegations of exaggerated advertising, but a bribery investigation may be the real aim for authorities.
Japan Tobacco brings Stribild home after U.S./EU launches by Gilead. Johnson & Johnson reduces patient burden with higher dose Prezista.